Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19656294 | 0.84 | FFAR1 (0.43) | FFAR1DGAT1SYKFAAHLPL | |
| SCHEMBL4099087 | 0.80 | FFAR1 (0.57) | FFAR1DGAT1HIF1ASYKFAAH | |
| SCHEMBL20399992 | 0.78 | FEN1 (0.41) | ROCK1FFAR1LPLLIPGFEN1 | |
| SCHEMBL5538625 | 0.77 | ROCK1 (0.43) | ROCK1DGAT1PDK2HIF1APDGFRB | |
| SCHEMBL25414529 | 0.73 | FFAR1 (0.46) | FFAR1DGAT1PRMT5WDR77LPL | |
| SCHEMBL24896681 | 0.72 | BACE1 (0.40) | ROCK1FFAR1DGAT1HIF1APRMT5 | |
| SCHEMBL22448097 | 0.72 | FFAR1 (0.46) | FFAR1DGAT1LPLLIPG | |
| SCHEMBL14710834 | 0.71 | ROCK1 (0.60) | ROCK1DGAT1HIF1APRMT5WDR77 | |
| SCHEMBL22642936 | 0.69 | KCNH2 (0.53) | CTSKCTSCKDR | |
| SCHEMBL17939899 | 0.69 | ROCK1 (0.52) | ROCK1DGAT1HIF1APRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11213520-B2 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-04 | — | — | US | disclosed |
| EP-3464267-B1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-23 | — | — | EP | disclosed |
| US-20190290637-A1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213520-B2 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | CDK9, CDK19, CDK8 | ROCK1 883/4885FFAR1 4806/4885DGAT1 4341/4885 |
| US-20190290637-A1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | CDK9, CDK19, CDK8 | ROCK1 875/4885FFAR1 4790/4885DGAT1 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.